Second Dupixent® (dupilumab) Phase 3 eosinophilic esophagitis trial to demonstrate significant disease improvements, underscoring role of type 2 inflammation in this complex disease

Amy Giles
Increasing Engagement

Daniel Sontupe
Market Access

Suma Ramadas, PhD
Medical Affairs

Joey Cohen
Medication Adherence

Liz Kane
Impactful Strategy

Stacey Gandler
Brand Nourishment

Matt Turner
Patient Affordability

Matthew Durham
Omnidynamic Marketing

Brenda Snow
Authentic Patient Voice

David Linetsky
Point-of-Care Marketing

Pat Purcell
Meeting Engagement

Paul Theisen
Patient Acquisition

Bud Bilanich
Success Coach

Frank Burrell
Scientific Storytelling